BTIG Initiates Coverage On Magenta Therapeutics with Buy Rating, Announces Price Target of $20
BTIG analyst Yun Zhong initiates coverage on Magenta Therapeutics (NASDAQ:MGTA) with a Buy rating and announces Price Target of $20.
The Week Ahead In Biotech: ASCO Presentations Front And Center, FDA Decisions Due For Scynexis, Liminal And Alkermes
After having declined through the first half of the week, biotech stocks staged a recovery to close higher in the trading week ended May 28. Broader market sentiment and company-specific news flow dictated stock moves during the week.